



Annual Report 2025

Driven to make a lasting difference to
the health of all New Zealanders.



Contents

About us	1
Foreword from the Chair	2
CEO Report	3
Board of Trustees	4
Senior Management	6
Research Physicians	7
What we do	8
General performance dashboard	9
Clinical performance dashboard	10
Why we do what we do	11
How we benefit the community	12
2025 Highlights	13
Trust outcomes	15
Whangārei Research Day	16
Participant stories	17
Staff Awards	19
Grant-funded trials and highlights	20
Commercial trials.....	23
Commercial trials – feasibilities	24
Areas of research – activity by department	26
Reserve balances	31
Publications	32



About us

Aotearoa Clinical Trials (ACTT) is New Zealand's largest public hospital-based clinical trial provider, with over two decades of experience advancing world-class medical research.

We operate fully integrated research units at Middlemore Hospital in South Auckland and Whangārei Hospital in Te Tai Tokerau – Northland, collaborating with more than 25 hospital departments across a wide range of therapeutic areas – from oncology, cardiology, and haematology to diabetes, paediatrics, respiratory health, renal care, and surgery.

As an independent Charitable Trust, ACTT reinvests surpluses directly into research and capability building. This purpose-driven model strengthens hospital departments, supports Research Fellows, nurses, and training needs. It ensures participants benefit from the very latest in clinical care.

Our multidisciplinary team of research nurses, coordinators, pharmacists, regulatory specialists, and clinicians deliver safe, ethical, and efficient trials. ACTT holds an international accreditation (IAOCR) for managing sites of clinical excellence, reflecting our commitment to the highest standards of quality and compliance.

We are proud of our strong community partnerships, particularly with Māori, Pasifika, and Asian populations who have historically faced barriers to healthcare. By embedding trials in public hospitals, we expand access to innovative therapies, reduce inequities, and create lasting health benefits for communities across Aotearoa.

Our mission is simple: to improve health outcomes and equity nationwide, while ensuring New Zealand plays a leading role in clinical research worldwide.



ACTT holds both GCSA certification and workforce quality accreditation, and was the first research organisation in New Zealand to achieve these standards.

Foreword from the Chair



Greg Batkin
Chair

The 2025 financial year marked a turning point for Aotearoa Clinical Trials. Following a challenging 2024, trial activation numbers have rebounded, fuelled by a record number of feasibility requests, with that rebound continuing strongly into the start of FY26. This is a clear sign of continued sponsor confidence in the speed, quality, and collaborative approach that defines ACTT.

The opening of a Phase I overnight facility, a dedicated Pharmacy Reconstitution Unit, and a new site in Botany reflect a strategy to strengthen early-phase research and widen access to trials across our communities. Together, these initiatives underpin ACTT's ability to deliver world-class research while remaining grounded in our charitable mission to benefit the communities we serve.

That mission remains front and centre. In FY25, more than \$730,000 from our designated and restricted reserves was invested in Fellows, nurses, training, and departmental research support. This reinvestment ensures that hospitals in Counties Manukau and Te Tai Tokerau are equipped to deliver more high-impact trials, translating directly into improved care for patients in the communities of South Auckland and Northland.

The Board acknowledges the excellent participant survey results, with 94% rating their experience as excellent and 100% recommending participation. These outcomes show that ACTT's growth is matched by the quality of its care and the trust it earns.

On behalf of the Board, I thank the CEO, management, our investigators, hospital partners, staff, and most importantly the participants who make this work possible. With strong governance, sustainable reserves, and a clear strategic pathway, ACTT is well positioned to deliver even greater impact for Aotearoa in the years ahead.

Finally, on behalf of my fellow Trustees, I'd like to thank Dr. Pete Watson and Mr. Andrew Connolly for their highly valued contributions to the Board.

Dr. Pete Watson joined the Board in April 2020 and left to take up the position of Executive Regional Director South Island / Te Waipounamu having served five years as Trustee.

Mr. Andrew Connolly was a Trustee from 24 April to 7 July 2025 and resigned to become a Board member and Deputy Chair of Health New Zealand.

We wish both the very best in their very important new roles.

Greg Batkin
Chair, Aotearoa Clinical Trials

CEO report

FY25 has been a year of delivery, innovation, and growth for Aotearoa Clinical Trials. We invested in infrastructure that strengthens our ability to run complex studies, including a hospital-based Phase I overnight facility, fully integrated eSource paperless trial file system and a Pharmacy Compounding Unit at Middlemore. These developments expand our capacity while keeping participant care at the centre of everything we do.

Our Grants Programme achieved record success: 65 grant-funded studies supported, 19 new projects activated, and around \$3 million secured in research funding. Notable highlights include Health Research Council (HRC) awards for the REPORT and BALANCE+ studies, and progress towards launching the ROADMAP platform trial in New Zealand. This “virtuous cycle” leveraging commercial trial revenue to support investigator-initiated and collaborative research remains a unique strength of the ACTT model.

Operationally, we maintained international accreditation as a research site of excellence, confirming our systems and processes are world-class. Sponsors continue to recognise our speed and data quality, demonstrated by record feasibility requests over the past year. Our participant surveys remain a source of pride: 95% rated our staff’s friendliness as excellent, and 100% would recommend trial participation to others.

Partnerships are central to our work. Our collaboration with Middlemore and Whangārei Hospitals deepened further, while our engagement with manawhenua and Pacific health providers ensures research is accessible and relevant to the communities we serve. This has been reflected through our sponsorship of the Middlemore Hospital Staff Awards, support of KidzFirst Christmas toys appeal for children and the major sponsor of Middlemore Research Week and the Research Day at Whangārei Hospital.

Looking ahead, we are focused on expanding our early-phase capacity, strengthening regional delivery, integration of AI-based systems with our operational framework and broadening access to novel therapies across Aotearoa. None of this is possible without the dedication of our staff, investigators, Board, sponsors, and participants, to whom I extend my sincere thanks. Together, we are shaping a healthier future for the communities we serve through research.

Dr. Edward Watson

CEO, Aotearoa Clinical Trials



Dr. Edward Watson
Chief Executive Officer

Board of Trustees FY25



Greg Batkin

Greg brings to the Board a range of commercial, financial and strategic skills. Greg has had experience in various business sectors, including automotive, energy, agriculture and life sciences. In addition to his role as Chairperson of ACTT, Greg is Deputy Chair of Safer Sleep (an anaesthetic software company), a director of a large private business based in South Auckland, and a Trustee of Cancer Research Trust New Zealand.



Dr. Pete Watson

Pete is a medical graduate of Otago University and completed his specialist training as a Paediatrician. He began his career as a Consultant at Counties Manukau Health and as a clinical academic at the University of Auckland in 1996. Pete worked at CMH until 2022, contributing to Child and Youth Health, Mental Health & Addictions. He has held various local, regional and national clinical leadership roles, most recently he has been the Chief Medical Officer, Deputy CEO and then Acting CEO at Counties Manukau DHB. Following the formation of Te Whatu Ora, Pete moved into the Interim Te Whatu Ora National Medical Director role until June 2023.



Sanjoy Nand

Sanjoy is currently the Chief of Allied Health Scientific and Technical at Te Whatu Ora, Counties Manukau. He is an experienced health sector leader with a background in clinical and operational leadership roles within the New Zealand public healthcare system. Originally trained as a pharmacist, Sanjoy also has extensive knowledge and experience in the pharmaceutical sector. He is a Chartered Member of the Institute of Directors.



Kevin Wightman

Kevin graduated in Pharmacology from Nottingham University in the UK and has worked in Clinical Research in Australia and New Zealand for over 25 years. He is passionate about improving the delivery of clinical trials to better meet patients' needs, with more than 30 years' experience in leading Pharma, CRO, site, and patient centric solution providers across Asia Pacific, the US and Europe. Kevin is a member of the Australian Institute of Company Directors (AICD) and brings unique perspectives, stakeholder networks and insights from both industry and site angles, drawing on his Board and Non-Executive Director experience with industry associations and not-for-profit organisations.



Whetumarama Parore

Ngāti Whātua, Ngāpuhi, Ngāti Kahu and Ngāti Poneke

Marama has worked in the New Zealand health sector for over 30 years, for a range of organisations and NGOs, in roles such as the General Manager Māori Health and Access & Optimal Use for PHARMAC and Pou Ahorangi – CEO for Te Rau Matatini the National Māori Mental Health and Addiction workforce, Te Aka Whai Ora – Māori Health Authority as Whānau Voice Lead and Whaikaha – Ministry of Disabled People. Marama is a trustee of Te Houhanga Marae and Pipitea Marae in Wellington. Marama lives in Porirua with 20 mokopuna (grandchildren) and one moko tuarua (great grandchild) who also whakapapa to Ngāti Toa.



Michael James

Michael's international career has spanned commercial and financial leadership roles across hi-tech and innovation industries in both public and private sectors. He is an experienced director in the infrastructure and innovation sector and brings a wealth of commercial and strategic thinking expertise to the Board.

Mr. Andrew Connolly served as a valued member of our Board from April to July 2025, before being appointed Deputy Chair of the Board of Health New Zealand.

Senior management

Operations team

The Operations team led by Karen Carter plays a critical role in delivering high-quality, efficient clinical trials across ACTT's Middlemore and Whangārei sites. This multidisciplinary team collaborates closely with investigators, hospital departments, sponsors, CROs, regulatory bodies, and third-party providers to ensure the seamless coordination of nursing, phlebotomy, laboratory, eClinical, and pharmacy services.



Karen Carter
Research Operations
Manager

People, safety, and quality are at the heart of our work. Over the past year, key milestones have included the successful growth and integration of the Whangārei team, and the promotion of several team members – reflecting the strength of ACTT's internal career development pathways.

Finance team

The Finance team led by Emani Stefano provides essential financial management and oversight to ensure the stability and sustainability of ACTT's operations. We are responsible for budgeting, reporting, compliance, and resource allocation, supporting the organisation to meet its obligations and plan for future growth.



Emani Setefano
Finance Manager

By adopting digital tools and improving processes, we help streamline operations and enable clinical teams to focus on delivering high-quality research. The team's work is underpinned by integrity, accuracy, and a commitment to supporting ACTT's long-term success.

Business team

The Business team led by Kate Msiska manages the end-to-end process for sourcing and set-up of ACTT's commercial research portfolio.



Kate Msiska
Business Manager

This includes business development, feasibility assessments, budget negotiations, contract management, regulatory processes, set-up logistics and sponsor and investigator relationship management.

With a team of four, including the Business Manager, a Regulatory Lead and two Start-up Specialists, we focus on building strong foundations for every trial, ensuring compliance, efficiency, and trusted collaboration with commercial partners.

Our work enables ACTT to expand access to innovative clinical trials that benefit patients and support the health system.

Grants team

The Grants team, led by Dr. Nicola Jackson, enables high-impact, non-commercial research by supporting clinicians through every stage of investigator-led studies. We work alongside researchers to secure funding, manage trials, and share results, helping to bring public-good research to life and extend the reach of ACTT's impact.



Dr. Nicola Jackson
Grants Manager

Our work is underpinned by a commitment to innovation, collaboration, and equity of access. By reinvesting commercial trial revenue into non-commercial studies, we ensure ongoing innovation, improved patient care, and long-term benefits for the health system.

Research Physicians team

ACTT partners with recognised Research Physicians who bring extensive expertise from their work in affiliated hospitals and community general practices.

These physicians play a vital role in supporting departments interested in research but lacking the time or resources to conduct studies independently. Collaborating closely with the clinical trial operations team, including trial coordinators and nurses, they help facilitate high-quality clinical trials across a wide range of medical specialties. This collaboration expands research opportunities for patients throughout Aotearoa New Zealand.

Their involvement strengthens the connection between research and clinical care, ensuring more patients can access innovative treatments and benefit from research-driven healthcare.



Dr. Renate Koops
Clinical Director and
Research Physician

Research Physicians

Dr. Rita Kettoola

"It's a real privilege to work alongside trial participants in innovative research. There's something truly exciting about seeing new treatments years before they reach the wider community, and knowing that our work helps shape the evidence that guides their future use."



Dr. May Lim

"I am very excited to be part of groundbreaking medical advancements that improve patient outcomes and help shape the future of healthcare. I appreciate that clinical research allows me to maintain a strong element of patient contact when assessing trial participants, while also engaging in important non-patient-facing work."



Dr. Ian Rosen

"My main motivation for involvement in clinical research is being at the forefront of new medications that are in development for diseases such as diabetes and lipid disorders."



Dr. Aritra Ray

"What motivates me to work in clinical research is the team spirit and the generosity of volunteers who give their time and health to further medical advancements."



Dr. Joanna Wojciechowska

"If I can help to save even one life - then everything makes sense."

What we do

As New Zealand's largest independent, public hospital-based clinical trial provider, ACTT is dedicated to improving health outcomes nationwide.

Our diverse portfolio spans commercial, grant-funded, collaborative, and investigator-initiated trials, advancing medical research while giving New Zealand access to innovative therapies that might not otherwise be available.

Clinical trial management is our core expertise, and we are proud to be recognised specialists in this field.

Commercial trials

Commercial trials are central to our work. Partnering with international biopharmaceutical companies, we deliver Phase I to Phase IV studies across a broad range of therapeutic areas. These trials bring cutting-edge treatments to the local communities while contributing to global advancement in medicine.

Grant-funded trials

Grant-funded trials, supported by government agencies such as the Health Research Council, philanthropic organisations, surpluses from our commercial trials and contributions from other research groups address priority health challenges for New Zealand. They range in scale, duration, and complexity, and include both collaborative group or investigator-initiated trials.

Collaborative group trials

Working with national and international research networks, collaborative group trials unite leading clinicians, researchers and institutions to deliver impactful studies. This cooperative approach strengthens research capacity and ensures findings are relevant to the populations we serve.

Investigator-initiated trials

In investigator-initiated trials, researchers lead the entire process, from concept and protocol development, to securing funding and managing the trial, often exploring novel ideas or niche health questions. These studies foster innovation and ensure research reflects New Zealand's unique health needs.



General performance dashboard FY25

STAFF



ALL STAFF

Total staff including contractors who worked at ACTT during FY25

60

RESEARCH STAFF

Includes Nurses, Clinical Trial Coordinators, Phlebotomist and Pharmacists

35

TRIAL METRICS



COMMERCIAL TRIALS

Total number of commercial trials underway in FY25

74

GRANT FUNDED TRIALS

Total numbers of active grant funded/ Investigator-led trials in 2025

77

NEW TRIAL ACTIVATIONS

Commercial trials activated during FY25

23

COMMERCIAL FEASIBILITIES

Total feasibilities received during FY25

236

COMMERCIAL PARTICIPANT METRICS



NEW TRIAL PARTICIPANTS

311

TOTAL PARTICIPANTS

Includes ongoing multi-year trials

637

REVENUE



TOTAL REVENUE

\$11.8m

RESERVES

\$7.4m

RESERVES SPENT

Designated / restricted revenues spent on research activities during the year

11%

GRANT REVENUES

Designated / restricted revenues spent during the year

\$2.4m

Clinical performance dashboard FY25

HOSPITAL ACTIVITY (Departments and investigators)



ACTIVE DEPARTMENTS

Number of hospital departments we worked with in FY25

26

Middlemore 19 | Whangārei 7

ACTIVE INVESTIGATORS

Number of investigators involved in commercial and grant trials in FY25

88

Middlemore 77 | Whangārei 11

COMMUNITY CONTRIBUTIONS



REIMBURSEMENTS

Reimbursements to our community for taking part in Clinical Trials

\$409k

OUTPATIENT ACTIVITY



OUTPATIENT VISITS

Total outpatient visits during the course of trials

4151

MONEY SAVED

Estimated money saved by service outpatient visits

\$1.45m



Why we do what we do



At ACTT, our mission is to improve health equity across New Zealand. By removing barriers to healthcare access and building trust in world-class clinical research, we aim to make a meaningful difference in the lives of our communities.

New Zealand faces disparities in access to high-quality healthcare. ACTT addresses these inequities by improving access to clinical trials giving participants the opportunity to receive innovative therapies and take a more active role in their own health. Participation in these trials not only improves individual outcomes but also strengthens confidence in medicines and clinical research for future generations.

Clinical trials are often the only way patients can access cutting-edge therapies that may be standard in other countries but not funded in New Zealand. We conduct trials where the comparator medicine is considered the 'gold standard' in the USA, UK or Europe but often unavailable here in New Zealand. This provides

participants with access to these medicines and physicians valuable experience in their use.

We partner with leading biopharmaceutical and medical device companies from around the world to bring novel therapies to New Zealand and work closely with public hospitals to deliver them where they are needed most. Our network enables leading health investigators to offer world-class treatments to participants in their own regions.

New Zealand offers a competitive advantage for global clinical research, with rapid trial setup and strong recruitment performance. At ACTT, our highly experienced team is committed to growing the number of clinical trials conducted here, expanding access to novel treatment and improving health outcomes for our communities across the country.

How we benefit the community

ACTT, in partnership with Middlemore and Whangārei Hospitals, is dedicated to improving health outcomes in the Counties Manukau and Te Tai Tokerau communities by increasing access to clinical trials. These trials provide early access to advanced treatments, improve patient care and help reduce health inequities.

Enhancing access to personalised care

Clinical trials at ACTT offer participants dedicated time with specialist nurses, coordinators, and investigators. This personalised, participant-centred care fosters strong relationships between participants and the care teams, supporting better engagement, improved adherence to treatment, and stronger health outcomes.

Improving health outcomes through research

Participation in clinical trials is associated with improved outcomes when compared to standard care. Research at Middlemore Hospital, for example, has shown significantly lower mortality and an 80% reduction in cardiovascular-related deaths among trial participants over a three year period.¹

Access to cutting-edge treatments

Clinical trials often provide access to breakthrough therapies not yet available through New Zealand's public health system due to funding or regulatory delays. These treatments are provided at no cost to participants, offering meaningful improvements in quality of life well before broader public availability.

Reducing health inequities

ACTT's work plays an important role in reaching communities that have historically experienced barriers to healthcare, including Māori, Pasifika, and Asian populations. By embedding clinical trials within public hospitals and offering earlier access to care and novel treatments, ACTT contributes to more equitable health outcomes across Aotearoa New Zealand.


Supporting economic and social wellbeing

In the past year alone, ACTT reimbursed over \$409,000 to trial participants to support travel, time away from work, and other associated costs. This financial support reduces the burden on participants and enables more people to participate in research and focus on their health without cost being a barrier.

Building trust through engagement

ACTT is committed to raising awareness about clinical trials through direct community engagement. By connecting with local residents, we build trust, share knowledge, and promote understanding of the benefits of research participation, ensuring our work remains grounded in the needs of the community we serve.

Ethnicity mix of trial participants at ACTT FY25



¹Baker, J.R., Vandal, A.C., Yeoh, J., Zeng, I., Wong, S., Ryan, S.N. Clinical trial participation improves outcome: A matched historical cohort study. *Clinical Trials*. 2013;10(5):735-743. doi:10.1177/1740774513496915

2025 Highlights



The new Phase I overnight stay facility within Middlemore Hospital.

Expansion of early-phase research capability

In early 2025, ACTT opened a Phase I overnight stay facility within Middlemore Hospital, marking a significant milestone in expanding support for early-phase clinical trials. The unit enables extended participant monitoring and intensive sampling, critical components of early-phase trials.

Participants can transition seamlessly from ACTT's fully equipped infusion suite to the overnight facility, where 24/7 clinical oversight is provided by experienced staff. This development strengthens ACTT's ability to safely and effectively deliver complex trials across the full spectrum of clinical development.

"The ability to accommodate participants overnight ensures we can meet the complex requirements of Phase I trials while maintaining a strong focus on participant care," said Karen Carter, Director of Clinical Operations.

Leadership growth at Whangārei site

In September 2024, Kayley King joined ACTT as Site Manager for Whangārei. Kayley brings extensive experience in both commercial and investigator-initiated trials, having worked in the UK and New Zealand.

Since joining, she has played a key role in the launch of SurgTrials – a national surgical trial network and supported the growth of both commercial and grant-funded research in new therapeutic areas. Her leadership and commitment are already making a meaningful impact on research delivery and community health outcomes in Te Tai Tokerau Whangārei.

Kayley's appointment reflects ACTT's ongoing investment in regional capability and our commitment to strengthening research access for patients in Northland.

A milestone in clinical research

In April 2025, the Surgical Trials Network – New Zealand (SurgTrials, www.surgtrials.com) was officially launched, marking an exciting new chapter in the nation's clinical research landscape. As a proud partner of Aotearoa Clinical Trials, they recognise the profound impact this initiative will have on the future of surgical research across Aotearoa. SurgTrials aims to drive innovation, enhance collaboration, and improve patient outcomes by supporting clinical research at all stages of development.

SurgTrials brings together surgeons, anaesthetists, nurses, and researchers committed to advancing evidence based practice. Sharing ACTT's vision to expand access to high quality clinical trials, SurgTrials fosters collaboration and excellence as a vital step toward elevating surgical care nationwide. The network provides comprehensive support for surgical researchers, from trial feasibility through to publication, empowering them to deliver impactful studies that strengthen careers and drive continuous improvements in patient care.

Dr. Ed Watson commented on the significance of this launch: "The establishment of SurgTrials represents a major development for surgical clinical research in New Zealand. By facilitating the connection of surgical researchers nationwide, this initiative strengthens our ability to conduct world-class surgical trials, and we are proud to play a role in this vital work."

Dr. Chris Harmston, Director and Scientific Lead of the network, emphasized the importance of decentralizing trial delivery to enhance collaboration across multiple centres. "Our goal is to elevate surgical research and ensure that it reaches all corners of New Zealand. SurgTrials empowers research surgeons to improve care and outcomes for all New Zealanders, regardless of where they live."



ACTT CEO Dr. Ed Watson with Dr. Chris Harmston

Key services offered by SurgTrials include:


- Trial feasibility assessments and research matchmaking
- Guidance on securing trial funding, ethical approvals, and regulatory compliance
- Support for Good Clinical Practice (GCP) training and certification
- Tools for data collection, quality assurance, and trial management
- Academic mentoring and publishing support

Led by Network Manager Kayley King, based at Whangārei Hospital in Te Tai Tokerau, SurgTrials offers tailored support to help professionals navigate the research process and collaborate with international partners. With a focus on increasing equitable access to clinical trials, the network ensures that innovative surgical care reaches all communities across New Zealand.

SurgTrials supports the excellent work performed to date by Dr. Harmston with the formation of the STRATA network (Surgical Trainee Research, Audit & Trials Aotearoa).

At ACTT, we are proud to support this transformative initiative and remain committed to advancing the future of surgical research in Aotearoa.

New pharmacy reconstitution unit opens



Aseptic reconstitution facility

In early 2025, ACTT Middlemore opened a dedicated Pharmacy Reconstitution Unit, designed to meet the growing demand for accurate and compliant preparation of investigational products.

The unit enables the safe reconstitution and handling of sterile products – enhancing oversight, quality, and efficiency in complex clinical trials.

This has enabled ACTT to be involved in novel CRISPR trials and make new technology available to our Counties Manukau community.

This investment strengthens ACTT's capacity to support Phase I-IV trials across a wide range of therapeutic areas, contributing to faster, more reliable outcomes for trial participants and sponsors alike.

Trust outcomes

ACTT operates as a Charitable Trust, with a mandated commitment to reinvest in research at Middlemore and Whangārei Hospitals.

Trust funds are held as general reserves or departmental allocations. Each year, these funds are used to strengthen research capacity within hospital departments, supporting roles such as Research Fellows and Nurses, and enabling staff to attend medical conferences that contribute to clinical and research excellence.

This ongoing investment reflects ACTT's purpose-driven model, ensuring that research activity continues to grow and deliver benefits for both healthcare teams, the communities they serve and add value to the partnering hospitals.

Departmental breakdown of granting from designated reserves

Type	Designated Reserve
Research Fellows	295,031
Nurses	230,584
Clinical Research funding	94,551
Conferences	78,330
Training	7,635
Patients Reserve parking	5,217
Database Support	4,530
Others	18,220
Total	734,099

Whangārei Research Day

In June 2025, ACTT hosted Whangārei Research Day, a landmark event bringing together clinicians, researchers, participants, and community leaders to celebrate and advance research in Te Tai Tokerau.

With a focus on collaboration and local empowerment, the day offered a platform to explore the unique challenges and remarkable opportunities of conducting clinical trials in regional and rural Aotearoa.

Highlights from the day

International Inspiration

Prof. Thanos Saratzis and Prof. Thomas Pinkney, both from the UK shared insights from global vascular and surgical trials.

The event also marked the official launch of the Surgical Trials Network (SurgTrials), a new platform for research collaboration across Aotearoa.

Local Leadership

Presentations from ACTT leaders focused on provincial research innovation, and a powerful participant story reminded us all why we do this work.

Collaboration in Action

An interactive session, RANDOMUNCH, allowed attendees to experience randomisation first-hand while learning about ethical dimensions of trial participation.

"Whangārei Research Day was a celebration of what's possible when research is embedded in the heart of local communities.

It showed how collaboration, curiosity, and clinical trials can come together to increase trial activity, build research capability, and ultimately improve health outcomes – right here in the region."

– Kayley King, Site Manager

A day that mattered

Feedback from attendees reflected a strong sense of pride and purpose. For many, this was the first time seeing research celebrated in a regional hospital setting, and for some, the first time they felt invited to join the world of clinical trials.

What attendees said:

"The whole event had heart – and purpose. I left feeling inspired."

"Hearing a participant speak so honestly about their experience changed how I see my role in research."

"Finally, we have a research presence in Northland. This is just the beginning."

Looking Ahead

The success of Whangārei Research Day 2025 highlights a growing appetite for local, inclusive research. ACTT is committed to building on this momentum, supporting clinicians, elevating Māori input, and bringing new trials to our region.

Acknowledgements

To our speakers, Medtronic (our sponsor for the day), attendees, and the participant who shared their story – thank you for making this a day to remember.

Active grant studies in Whangārei

- The Randomised, Double-Blinded, Placebo-Controlled Trial of Early, Short Course Oral Dexamethasone for the Treatment of Sydenham's Chorea in Children (TREAT-SC) study led by Dr. Ailsa Tuck (Paediatrics)
- The Post-Endoscopy Tumour Study (POET) led by Dr. Chris Harmston and Dr. William Xu (Surgery)
- Implementation of Metformin therapy to Ease Decline of kidney function in Polycystic Kidney Disease Randomised Placebo-Controlled Trial (IMPEDE-PKD) led by Dr. Adam Mullan (Renal)
- The Chronic kidney disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE) led by Dr. Adam Mullan (Renal).

Participant stories

Participant survey highlights

Rate your overall satisfaction with ACTT?

83%

EXCELLENT

Rate the friendliness of our staff to you and your whānau?

95%

EXCELLENT

Would you recommend being involved in clinical research to others?

100%

EXCELLENT

How would you rate your overall experience in being involved in clinical trial?

94%

EXCELLENT

Rate the caring concern of our staff to you and helping you understand your condition?

92%

EXCELLENT

Main reasons for participating in a trial

Learn more about their condition

30%

To help future generations

42%

Access modern medicines

19%

Doctor's recommendation

11%

"I feel so lucky": Mary's story on the PionERA trial

When Mary was first diagnosed with breast cancer in 2021, she had every reason to believe that her journey would be short and manageable. A mastectomy followed by clean margins seemed to signal the end of it. "We thought that would be it," she recalled. "No further treatment, nothing more needed."

But cancer, as she would learn, doesn't always follow expectations.

Over the months that followed, Mary experienced not just one recurrence, but multiple. "I had another growth on the same side, then another. They were small, but relentless," she said. She underwent further surgeries, chemotherapy, and radiation in 2022 and 2023.

Still, she remained optimistic. "I've always just gone with the flow," she laughed. "I was more focused on trying to get my other breast removed, for symmetry, really. It sounds vain, but it's hard being lopsided."

A bone scan, almost incidental at the time, revealed something unusual. At first it looked like a congenital abnormality in the skull. A follow-up three months later told a different story: the cancer had metastasised.

Mary met Dr. Edmond Ang, an oncologist and the Principal Investigator for the PionERA trial, shortly after that diagnosis. "I walked into that room not expecting anything and walked out shocked. But also hopeful," she said. "Edmond was calm, warm, full of knowledge. He mentioned a trial that might be opening soon. I didn't know anything about clinical trials, but I trusted him."

The PionERA trial, sponsored by Roche, was soon open and Mary was eligible. In fact, she became the only participant enrolled in New Zealand. "That blew my mind. Why me?" she said. "But I feel incredibly lucky."



Kayley King (left) and Mary (right)

"It's like one big family."

Mary speaks with warmth and gratitude about the team supporting her through the trial.

"From Edmond and Kayley to the pharmacists, labs, my GP, everyone has been just amazing. It's like one big family. I feel so cared for."

The trial involves regular tests and monitoring: CT scans every two months, bone scans every six. "At first I thought, oh no, not another one. But now I find it reassuring. Every two months, I get to hear that things are stable. And they have been. Eight months in, and the cancer in my skull and nodes hasn't grown. That's a big win."

Mary's positive attitude is infectious, but she's honest about the occasional worries. "My daughter reminded me I was nervous at first, mostly about side effects. I was worried I'd be sick all the time. But I haven't had many side effects at all. I've been so lucky."

"I was so naïve... but now I think research is absolutely amazing."

Before this, Mary says she had little understanding of research or trials. "I was so naïve, I thought trials were just something they did overseas, or for people who'd run out of options. But it's not like that. It's about trying to find better treatments, and we all benefit from that."

She's been especially encouraged by the support built into the trial experience. "All my appointments, scans, tests, it's all covered. My time is the only cost, and I've got a supportive husband who drives me when I need."

Asked if she thinks she's making a difference, she hesitates. "I don't know. I hope so. I'm just one person. But if this helps someone else down the line, then I'm proud of that."

"I'm still here. I feel amazing."

Despite everything, Mary describes her cancer journey as one of surprising grace. "I've never really felt it. No anxiety, no big drama. I just take it as it comes."

Later this year, she's looking forward to something even more special: her first grandchild. "Our youngest got married last year, and now we've got a baby coming in November. I'm still here. I feel amazing. And I'm just so grateful."

For others considering taking part in a clinical trial, she has simple advice:

"Go for it. You never know how it could help - not just you, but others too."

Staff Awards 2025



Dr. Nicola Jackson

THE ACTT AWARD

For consistently demonstrating the Company Core Values through their thoughts and actions.



Mhairi McIntyre

CERTIFICATE OF EXCELLENCE

For consistently demonstrating excellence through their efforts and interactions with other staff.



Anne Kendall

CERTIFICATE OF EXCELLENCE

For consistently demonstrating excellence through their efforts and interactions with other staff.



Grant-funded trials and highlights

ACTT has significant expertise in managing non-commercial/grant funded research. This includes both investigator-initiated and collaborative group studies that typically contribute to public good and provide insight into unmet patient and physician needs. This research can foster new international collaborations, drive policy change, and enable access to treatments that would otherwise be unavailable to patients in Aotearoa New Zealand.

Involvement in such research also allows researchers to develop the academic side of their career, including involvement with academic centres around the world, journal article publication and recognition as leaders in their respective fields.

Many departments are involved in both commercial and non-commercial/grant funded research, leveraging the revenue generated from commercial research to support investigator-initiated and collaborative group studies. This 'virtuous cycle' is a strength of the ACTT model, as research funds are specifically ringfenced to support future research activity within the departments.

ACTT has a dedicated Grants team that supports clinical researchers at Middlemore and Whangārei Hospitals. This support includes securing research funding, refining protocols, creating budgets, obtaining regulatory approvals, managing trials and data, recruiting participants, and providing medical writing services. Such services are essential to enable busy clinicians in public hospitals to continue their academic pursuits and contribute to a culture of research excellence.

The Grants team is led by Grants Manager Dr. Nicola Jackson, supported by two PhD-qualified Grant Portfolio Managers (Drs. Sumudu Ranasinghe and Alexandra Mowday), a Clinical Research Coordinator (Kate Wong She), and a Research Coordinator (Georgia Fowler).

FY25 was ACTT's most successful year to date, with the Grants team supporting 65 grant funded clinical trials and research projects. 19 new studies were activated across the disciplines we support, including Respiratory, Paediatrics, Renal, Anaesthetics, Gastroenterology, Stroke, Emergency Care, ICU, and Infectious Diseases. The Grants team also supported our investigators to secure over \$2.8 million research funding.

Funding successes:

REPORT study

The REducing the PrOgression of diabetic kidney disease: A cluster Randomised Trial (REPORT) led by Dr. Viliame Tutone and Dr. Kalpa Jayanatha (Renal Department) at Middlemore Hospital was awarded a Health Research Council 2024 Health Delivery Research Project Grant valued at \$1,399,437. This grant will support an innovative project aimed at tackling diabetic kidney disease (DKD) in Auckland. The project team includes Dr. John Baker, Dr. David Simmons, Dr. Joanna Dunlop, and Dr. Sumudu Ranasinghe from the wider Health New Zealand Counties Manukau and ACTT teams.

This initiative was identified by our local investigators, who recognised a critical gap in managing DKD during its early stages. Their vision has evolved into a collaborative partnership between primary healthcare organisations (PHOs) and secondary care services. Several prominent PHOs in the region, including ProCare, National Hauora Coalition, and Tamaki Health, are key collaborators in the project. Proudly hosted by ACTT, the team is working together to address this significant healthcare challenge, with the potential to influence nationwide healthcare policy.

DKD is a serious complication of type 2 diabetes mellitus, affecting around 228,000 individuals in New Zealand, and is the leading cause of end-stage kidney disease. The project aims to reduce the progression of DKD by introducing a new integrated model of care in the metro-Auckland area. This approach addresses the care gap by providing primary care with additional resources, such as enhanced patient education, specialised training for healthcare professionals, and a platform for ongoing collaboration with diabetes and renal specialists. Through this model, primary care teams will receive expert guidance to identify patients who could benefit from intensified care and deliver it effectively.

The project is due to start in late 2025.

BALANCE+ study

The BALANCE+ study, A Platform Trial for Gram Negative Bloodstream Infections, led by Dr. Susan Morpeth (Infectious Diseases Department) at Middlemore Hospital has been awarded a Health Research Council 2025 Project Grant valued at \$1,439,950.

This study investigates the safest and most effective antibiotics to use in hospitalised adults with Gram-negative bloodstream infections. It compares treatment approaches, including targeted or oral antibiotics, while also incorporating patient and whānau perspectives to support equitable care. Findings will aim to improve antibiotic use, reduce antibiotic resistance, improve health outcomes, and support health system sustainability.

BALANCE+ is an international trial coordinated by the Sunnybrook Research Institute (Canada). The project team includes infectious diseases experts from around New Zealand, Australia and Canada.

The project is scheduled to start in late 2025 and we look forward to sharing updates as the work progresses.



Infusion unit preparation

ROADMAP

The Randomised Arthroplasty Infection Worldwide Multidomain Adaptive Platform Trial (ROADMAP), led by Dr. Tom Hills (MRINZ) and Dr. Chris Luey (Infectious Diseases) at Middlemore Hospital, aims to identify the best management strategies for prosthetic joint infections (PJI). With Health Research Council funding in place from September 2024, the ROADMAP team have since successfully completed the ethics process and have obtained approval to conduct the trial in New Zealand. They have also been working closely with the Australian team to rigorously test the ROADMAP database ahead of the trial launch.

In parallel to this work, the lead investigators have begun engaging with interested investigators and sites from around NZ as they build towards recruitment to the trial in late 2025. Given the varying processes at each hospital, careful consideration of site-specific logistics (e.g., the most effective methods to identify eligible PJI cases) will be required. Initial ROADMAP sites are expected to include Middlemore, North Shore, Auckland, Tauranga, and Christchurch Hospitals, followed by extension to other sites across the country. Locality approval applications are underway at most sites, with approval already secured at Middlemore Hospital.

Expanding Department Engagement in FY25:

- **Anaesthetics (Middlemore):** Three new collaborative group trials (SNaPP, TRIGS, LOLIPOP) led by Dr. Julian Dimech and Samantha Ryan (Specialty Clinical Nurse – Research and Quality Assurance) were activated in FY25
- **Psychological Medicine (Middlemore):** One new investigator-initiated research project (DEL-REG-75) on establishing a clinical delirium registry, led by Dr. John Hopkins and was funded by the Ernest Hyam Davis and Ted and Mollie Carr Legacies (Perpetual Guardian)
- **Renal (Whangārei):** Two new collaborative group trials in Polycystic Kidney Disease and Chronic Kidney Disease (IMPEDE and CAPTIVATE), led by Dr. Adam Mullan were activated in FY25
- **Plastic and Reconstructive Surgery (Middlemore):** A new Research Coordinator role, established in October 2024 and funded by the Sir William and Lady Manchester Charitable Trust, is supporting rapid growth in research and audit across the Regional Plastic and Reconstructive Surgery Service. The role is held by Coordinator Kate Wong She (ACTT Grants Team) on behalf of the department.

Grant funded trials by department FY25

Middlemore	
Anaesthesia	3
Cardiology	2
Diabetes	2
Emergency Department	10
Gastroenterology	2
Haematology	5
Infectious Disease	4
Intensive Care	6
Neonatal	1
Ophthalmology	1
Paediatrics	25
Psychological Medicine	1
Renal	3
Respiratory	6
Stroke	1
Whangārei	
Emergency Department	1
Paediatrics	1
Renal	1
Surgery	2
Total	77



Commercial trials

Our focus on participant safety, high-quality data, and contractual and regulatory compliance ensure sponsors receive dependable, actionable results that support decision-making and regulatory approval. Participants can trust they are participating in safe, ethical research that may contribute to future medical advances. Our excellence as a clinical trial organisation is recognised in our recent re-accreditation by IAOCR (International Accreditation Organisation for Clinical Research).

Speed is crucial in clinical trials, and we excel in accelerating the process, from swiftly returning trial feasibilities and negotiating on contracts, assisting with obtaining ethics approvals and importantly the rapid recruitment of participants. This ensures that studies are activated and completed on time, maintaining the momentum that is vital in clinical research.

We take pride in our ability to recruit participants as quickly as possible, consistently striving to achieve or exceed our target recruitment for trials. We also foster strong relationships with our participants, ensuring they adhere to and complete the trials they are involved in. This enduring connection is reflected in their enthusiasm to participate in future studies. Our partnership with CROs and sponsors is important to us; we continuously strive to deliver the results we promise on every trial.

Our strengths

- **International accreditation:** (IAOCR) as a clinical trial organisation of clinical excellence
 - **Partnerships with leading clinicians:** Collaborations across over 25 hospital departments, ensuring diverse and expert oversight.
 - **Experienced research staff:** Our team is highly trained and operates within ICH GCP guidelines and our unit's Standard Operating Procedures.
 - **Rapid trial setup:**
 - Quick feasibility assessments
 - Smooth navigation through Institutional Review Board (IRB) and Independent Ethics Committee (IEC) processes
 - Start-up specialists who ensure timely agreement on budgets and contract negotiations
 - **Tailored recruitment plans:** Our recruitment team develops customised strategies for each trial to ensure we meet or exceed our recruitment targets.
 - **Access to diverse participants:** We leverage our strong partnerships with Counties Manukau and Te Tai Tokerau communities, and local Primary Care Organisations, along with sophisticated social media and advertising channels, to reach motivated participants.
 - **Dedicated pharmacy support:** Our specialised teams ensure compliant investigational product storage and preparation.
 - **Dedicated laboratory support:** Our specialised teams ensure compliant and timely sample processing and shipping.
 - **Leading edge Clinical Trial Management:** (CTMS) and feasibility management systems.
 - Paperless regulatory and participant files (eSource)
 - 24/7 remote monitoring access
- We are driven by a mission to improve health outcomes and reduce health inequities within our communities through world-class clinical trials.

Commercial trials – feasibilities

NEW FEASIBILITIES FOR CLINICAL TRIALS RECEIVED

FY24

243

FY25

247

Engagement by sponsors during FY25

4D Molecular Therapeutics
Acelyrin
Aligos Therapeutics
Allogene
Alnylam Pharmaceuticals
Alumis Inc
Amgen
Antiva Biosciences, Inc.
Apogee Therapeutics
Apollo Therapeutics
Arbutus Biopharma
Argenx
Arrowhead Pharmaceuticals
Ascentage Pharma Group
AstraZeneca
Bambusa Therapeutics
BeiGene
BioAegis Therapeutics, Inc.
BioDynamik, Inc
Biogen
Biohaven Therapeutics
Blueprint Medicines
Boehringer Ingelheim
Boston Pharmaceuticals
Bristol-Myers Squibb (BMS)
Centauri Therapeutics
Chiesi Farmaceutici
Chugai Pharmaceutical Co

Cidara Therapeutics Inc
Clover Biopharmaceuticals
Contineum Therapeutics
COUR Pharmaceutical Development
CSL Behring
Dignify Therapeutics
Douglas Pharmaceuticals
Dren Bio, Inc.
Eli Lilly
Evommune
Forte Biosciences
Generate Biomedicines
GigaGen
Gilead Sciences
GlaxoSmithKline (GSK)
Gossamer Bio Inc.
Hansoh Pharma
IDEAYA Biosciences
Immunovant, Inc.
Ingenia Therapeutics
Insmed
iProcess Global Research
Kartos Therapeutics
Kura Oncology
Marea Therapeutics
Mcure Biosciences Inc.
Moderna

ModeX Therapeutics
MSD
Neurocentrx
NGM Biopharmaceuticals
Novartis
Olema Pharmaceuticals
Oncoteq AG
Orion Corporation
OrsoBio
Ouro Medicines
Peptinovo Biopharma Inc.
Pfizer
Regeneron
Regulus Therapeutics Inc.
Renibus Therapeutics
Revolution Medicines
Roche
SAB Biotherapeutics
Sanofi
Syndax Pharmaceuticals, Inc.
Syqe Medical LTD
Terns Pharmaceuticals, Inc.
Thetis Pharmaceuticals
VarmX
Vertex Pharmaceuticals
Verve Therapeutics
Viage Therapeutics
Zai Lab

CROs

AK Clinical Research
Avance Clinical
Beyond Drug Development
CareAccess
Catalyst Clinical Research
Fortrea
HiRO

ICON Clinical Research New Zealand
InClin
Indero
IQVIA
Medpace
Novotech
PAREXEL International

PPD
Premier Research
PSI-CRO
SAPRO
Southern Star Research
Syneos Health
WCG Clinical



Extraction equipment at ACTT

FY25 ACTT commercial trial overview

Active commercial trials




New trials activated




FY25 commercial trials by study phase / type

- Device
- Phase I
- Phase II
- Phase III



FY24 commercial trials by study phase / type

- Device
- Phase I
- Phase II
- Phase III



Trials by recruiting departments in FY25

Department	Trials	Participants
ACTT Middlemore		
Cardiology	6	74
Dermatology	1	4
Endocrinology	7	115
Gastroenterology	5	17
General Medicine	1	45
Haematology	22	47
Hepatology	6	27
Intensive Care	1	1
Neonatal	1	8
Renal	1	4
Respiratory	8	38
Rheumatology	9	46
Stroke	1	6
Vaccinology	3	198
ACTT Whangārei		
Cardiology	1	9
Oncology	1	2
Total	74	637

Areas of research – activity by department in FY25

Many of these trials provide participants with access to treatments that are otherwise not available in New Zealand or not available for the condition under investigation.

Anaesthetics – Middlemore

GRANT-FUNDED TRIALS

3

Therapeutic Areas

- Anaesthetics Post-operative infection
- Anaesthetics Post-operative pain
- Post-operative pulmonary complications

Investigators

- Dr. Julian Dimech

Support Staff

- Samantha Ryan (Anaesthetics Research Nurse)

Cardiology (Middlemore)

COMMERCIAL TRIALS

6

GRANT-FUNDED TRIALS

2

Therapeutic Areas

- Acute Coronary Syndrome
- Atrial Fibrillation
- Chronic Heart Failure
- Coronary Artery disease
- Takotsubo Syndrome
- Transthyretin Amyloid Cardiomyopathy

Investigators

- Dr. Mayanna Lund
- Dr. Alana Vaai
- Dr. Andrew Borrie
- Dr. Craig Riddell
- Dr. Daniel Chan
- Dr. Danting Wei
- Dr. Douglas Scott
- Dr. Jen Li Looi
- Dr. Krishna Gupta
- Dr. Mansi Turaga
- Dr. Seungryul Simon Lee
- Dr. Stephen Li
- Dr. Timothy Sutton

Support Staff

- Chanthie Thach (Research Nurse)
- Jill Gilmore (Research Nurse)

Cardiology (Whangārei)

COMMERCIAL TRIALS

1

Therapeutic Areas

- Acute Coronary Syndrome

Investigators

- Dr. Daniel Chan
- Dr. Marcus Lee

Diabetes/Endocrinology (Middlemore)

COMMERCIAL TRIALS

7

GRANT-FUNDED TRIALS

2

Therapeutic Areas

- Bariatric Surgery
- Diabetic Kidney Disease
- Clinical Lipidology
- Dyslipidemia
- Familial Chylomicronemia Syndrome
- Obesity

Investigators

Dr. Ian Rosen
Dr. Joanna Wojciechowska
Dr. John Baker
Dr. Renate Koops

Support Staff

- Diabetes Foundation Aotearoa
- Kanchana Perera (PhD student)



Dermatology (Middlemore)

COMMERCIAL TRIALS

2

Therapeutic Areas

- Alopecia Areata
- Atopic Dermatitis

Investigators

- Dr. Paul Jarrett
- Dr. Amritpreet Singh
- Dr. Cheng Huang
- Dr. Leah Jones

Emergency Care (Middlemore)

GRANT-FUNDED TRIALS

10

Therapeutic Areas

- Bronchiolitis
- Concussion
- ED Adverse Events
- Febrile Convulsion
- Paediatric Neck Injuries
- Resuscitation
- Sepsis
- Septic Shock
- Traumatic Brain Injury
- Traumatic Haemorrhage

Investigators

- Dr. Eunicia Tan
- Dr. Andrew Brainard
- Dr. Christopher Lash

Support Staff

- Abbie Hamilton (ED Research Nurse)
- Alex Grigg (ED Research Nurse)
- Georgia Doyle (ED Research Nurse)
- Helen Barrett (ED Research Nurse)
- Sandra Neva (ED Research Nurse)

Department - Emergency Care (Whangārei)

GRANT-FUNDED TRIALS

1

Therapeutic Areas

- Concussion

Investigators

- Dr. Stephanie Richling

Support Staff

- Lucy Benjamin-Mitchell

Gastroenterology/Hepatology (Middlemore)

COMMERCIAL TRIALS

10

GRANT-FUNDED TRIALS

2

Therapeutic Areas

- Chronic Hepatitis B
- Crohn's Disease
- Eosinophilic Esophagitis
- Encephalopathy Decompensation in Cirrhosis
- Metabolic dysfunction-associated steatohepatitis
- Pancreatic Cancer
- Ulcerative Colitis

Investigators

- Dr. Adele Melton
- Dr. Emma Robinson
- Dr. Harry Yoon
- Dr. Hayneil Solanki
- Dr. Mirthe Van der Valk
- Dr. Sriharan Selvaratnam
- Dr. Tien Huey Lim
- Dr. Derek Luo

General Medicine (Middlemore)

COMMERCIAL TRIALS

1

Therapeutic Areas

- Muscle Strength and Endurance In Older Adults

Investigators

- Dr. Joanna Wojciechowska

Department - General Surgery (Whangārei)

COMMERCIAL TRIALS

1

Therapeutic Areas

- Post Surgery Drainage Device

Investigators

- Dr. Will Anderson
- Dr. Usha Shan

Haematology (Middlemore)

COMMERCIAL TRIALS

19

GRANT-FUNDED TRIALS

5

Therapeutic Areas

- Acute or Chronic Myeloid Leukemia
- Essential Thrombocythemia
- Multiple Myeloma
- Native Mantle Cell Lymphoma
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Relapsed or Refractory Follicular Lymphoma
- Relapsed/refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- Transplant ineligible multiple myeloma

Investigators

- Dr. Sharon Jackson
- Dr. Gordon Royle
- Dr. James Liang
- Dr. Kirsty Marshall
- Dr. Norman Quek
- Dr. Samar Issa

Infectious Diseases (Middlemore)

GRANT-FUNDED TRIALS

4

Therapeutic Areas

- COVID-19
- Pneumonia
- *S. aureus* bacteraemia

Investigators

- Dr. Genevieve Walls
- Dr. Susan Morpeth
- Dr. Natasha Pool

Support Staff

- Rima Song (ICU Research Nurse)
- Shirley Lawrence (Kidz First Research Nurse)
- Trent Herdman (ID Research Fellow)

Intensive Care Medicine (Middlemore)

COMMERCIAL TRIALS

1

GRANT-FUNDED TRIALS

6

Therapeutic Areas

- Cardiac Arrest and Resuscitation
- Community-acquired pneumonia
- Critical Illness
- Mechanically ventilated patients following trauma
- Metabolic Acidosis
- Sedation
- Severe community-acquired pneumonia

Investigators

- Dr. Tony Williams

Support Staff

- Rima Song (ICU Research Nurse)
- Tina Mwembani (ICU Research Nurse)
- Vivian Lai (ICU Research Nurse)

Neonatal (Middlemore)

GRANT-FUNDED TRIALS

1

Therapeutic Areas

- CPAP

Investigators

- Dr. Michael Meyer

Support Staff

- Lisa Mravich

Medical Oncology (Whangārei)

COMMERCIAL TRIALS

1

Therapeutic Areas

- Estrogen Receptor-Positive, Her2-Negative Advanced Breast Cancer

Investigators

- Dr. Edmond Ang
- Dr. Miriam Duffy

Ophthalmology (Middlemore)

GRANT-FUNDED TRIALS

1

Therapeutic Areas

- Keratoconus

Investigators

- Dr. Rasha Altaie

Paediatrics (Middlemore)

COMMERCIAL TRIALS

1

GRANT-FUNDED TRIALS

25

Therapeutic Areas

- Acute Rheumatic Fever
- Asthma/Wheeze
- Child Health Equity
- Childhood Respiratory illness
- Group A *Streptococcus* infection
- Implicit Bias
- Influenza
- Māori Child Health
- Measles
- Paediatrics
- Physiotherapy
- Preschool wheeze
- Recurrent Respiratory-Related Acute Lower Respiratory Infections
- Rheumatic Fever
- *S. aureus* bacteraemia
- Severe Respiratory Syncytial Virus Disease
- Sydenham's Chorea

Investigators

- Dr. Adrian Trenholme
- Dr. Adam Dennison
- Dr. Cameron Burton
- Dr. Catherine Byrnes
- Dr. Laura Rensford
- Dr. Rachel Webb
- Dr. Rebecca Alekzander

Support Staff

- Shirley Lawrence (Kidz First Research Nurse)
- Maricar Maminta (Kidz First Research Nurse)
- Gail Spence (Kidz First Research Nurse)
- Laarni Tundag (Kidz First Research Nurse)

Paediatrics (Whangārei)

GRANT-FUNDED TRIALS

1

Therapeutic Areas

- Sydenham's Chorea

Investigators

- Dr. Ailsa Tuck

Support Staff

- Kezia Schroyen

Psychological Medicine (Middlemore)

GRANT-FUNDED TRIALS

1

Therapeutic Areas

- Delirium

Investigators

- Dr. John Hopkins

Renal (Middlemore)

COMMERCIAL TRIALS

1

GRANT-FUNDED TRIALS

3

Therapeutic Areas

- Chronic Kidney Disease
- End Stage Kidney Disease
- IgA Nephropathy
- Peripheral Dialysis

Investigators

- Dr. Kalpa Jayanatha
- Dr. Hari Talreja
- Dr. Jamie Kendrick-Jones
- Dr. Oprah Pupi

Support Staff

- Jennifer Urquico (Renal Research Nurse)

Renal (Whangārei)

GRANT-FUNDED TRIALS

1

Therapeutic Areas

- Polycystic Kidney Disease

Investigators

- Dr. Adam Mullan

Support Staff

- Rudi Kok (Renal Research Nurse)

Respiratory (Middlemore)

COMMERCIAL TRIALS	8
GRANT-FUNDED TRIALS	6

Therapeutic Areas

- Acute Hypercapnic Respiratory Failure
- Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease And/Or Liver Disease
- Asthma
- Bronchiectasis
- Chronic Obstructive Pulmonary Disease
- Idiopathic Pulmonary Fibrosis (IPF) And Progressive Pulmonary Fibrosis
- Lung Cancer

Investigators

- Dr. Stuart Jones
- Dr. Conor O'Dochartaigh
- Dr. Conroy Wong
- Dr. Elaine Yap
- Dr. Grace Choy
- Dr. Ha Na Ahn
- Dr. Jeffrey Garrett
- Dr. Jeong Oh
- Dr. Leon (Hsien-Cheng) Chang
- Dr. Lydia Chan
- Dr. Paul Dawkins
- Dr. William Good

Rheumatology (Middlemore)

COMMERCIAL TRIALS	11
-------------------	----

Therapeutic Areas

- Active Psoriatic Arthritis
- Axial Spondyloarthritis
- Chronic and/or Subacute Cutaneous Lupus Erythematosus
- Moderate to Severely Active Systemic Lupus Erythematosus
- Rheumatoid Arthritis
- Sjögren's Syndrome

Investigators

- Dr. Mark Sapsford
- Dr. Amy Okamura-Kho
- Dr. Stanley Holt
- Dr. Sunil Kumar

Stroke (Middlemore)

COMMERCIAL TRIALS	1
GRANT-FUNDED TRIALS	1

Therapeutic Areas

- Stroke Prevention

Investigators

- Dr. Karim Mahawish

Support Staff

- Stroke Clinical Nurse Specialists

Surgery (Whangārei)

GRANT-FUNDED TRIALS	2
---------------------	---

Therapeutic Areas

- Rectal Cancer
- Colorectal and upper GI cancer

Investigators

- Dr. Christopher Harmston
- Dr. William Xu

Vaccine (Middlemore)

COMMERCIAL TRIALS	3
-------------------	---

Therapeutic Areas

- Extraintestinal Pathogenic Escherichia coli Disease
- Influenza Combination Vaccine
- Respiratory Syncytial Virus Disease

Investigators

- Dr. John Baker
- Dr. Aritra Ray
- Dr. Ian Rosen
- Dr. Kate Bradley
- Dr. May S Lim
- Dr. Rita Kettoola

Reserve balances

Designated + Restricted Reserve	Opening balance	Granting	% Of opening	Closing balance
Cardiology Capex Fund	1,589,481	140,260	9%	1,561,646
Dermatology Research Fund	31,840	326	1%	71,102
Diabetes Fund	55,616	1,539	3%	63,169
Emergency Care Clinical Research & Education	43,815	50,705	116%	44,569
Gastro Research Fund (incl's Hepatology)	457,594	38,121	8%	659,194
Haematology Research & Special Purposes Fund	1,480,712	59,832	4%	1,489,182
Home Health Fund	31,650	- 0		31,650
Intensive Care Unit Fund	743,486	60,745	8%	717,212
Infectious Diseases Research and Education Fund	153,966	913	1%	168,603
Kidz First Research Development fund	825,934	126,254	15%	799,743
Spinal Unit	24,428	- 0		24,428
Microbiology Fund	17,924	- 0		17,924
Neonatal Research	111,071	69,921	63%	107,407
Oropharyngeal Department Fund	8,742	- 0		8,742
Hand and Upper Limb Research Fund	161,060	65,920	41%	117,950
Radiology Research Fund	10,343	- 0		10,343
Renal Fund	63,009	12,643	20%	70,397
Respiratory Research Fund	519,018	4,337	1%	577,862
Rheumatology Research Fund	503,828	40,561	8%	572,928
Stroke Outcomes Fund	47,689	197	0%	48,992
Womens Health Fund	5,657	- 0		5,657
AT&R Research Fund	289	- 0		289
Anaesthetics & Surgical	4,905	1,982	40%	47,923
Orthopaedics	42,178	10,833	26%	32,147
Acute Allied Health	4,675	- 0		5,025
General Surgery	5,850	495	8%	31,481
Ophthalmology	1	- 0		249
Plastics	14,860	33,750	227%	50,493
Midwifery	1,300	- 0		1,300
Oncology	- 2,106	693	-33%	2,180
Mental Health	1,302	- 0		31,938
ARHOP	30,344	14,073	46%	24,220
	6,990,463	734,099	11%	7,395,447

General Reserve

Opening balance	2,049,296
Closing balance	2,057,259

Revenue

Commercial revenue	8,625,293
Non-commercial revenue [grants]	2,411,564
Other revenue	756,690
Closing balance	11,793,547

Publications FY25

Balance Investigators, f. t. C. C. T. G. t. A. o. M. M., Infectious Disease Canada Clinical Research Network, t. A., New Zealand Intensive Care Society Clinical Trials, t. A., the Australasian Society for Infectious Diseases Clinical Research, N., Daneman, N., Rishu, A., . . . the Australasian Society for Infectious Diseases Clinical Research, N. (2025). **Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections.** *N Engl J Med*, 392(11), 1065–1078. doi:10.1056/NEJMoa2404991

Bradbury, K. E., Earle, N. J., Rolleston, A., Fyfe, C., Grey, C., Korohina, E., Mehta, S., Cameron, V., Choi, Y., Devlin, G., Gladding, P. A., **Harrison, W.**, Henare, K., Kerr, A. J., Logue, G., Lumley, T., Pera, V., Pilbrow, A. P., Porter, G., Stewart, R., . . . Wall, C. (2025). **Dietary patterns of patients with acute coronary syndrome in the multi-ethnic New Zealand study of acute coronary syndromes (MENZACS).** *Nutrition, metabolism, and cardiovascular diseases : NMCD*, 35(9), 104037. https://doi.org/10.1016/j.numecd.2025.104037

Campbell, A. J., Anpalagan, K., Best, E. J., Britton, P. N., Gwee, A., Hatcher, J., Manley, B. J., Marsh, J., **Webb, R. H.**, Davis, J. S., Mahar, R. K., McGlothlin, A., McMullan, B., **Meyer, M.**, Mora, J., Murthy, S., Nourse, C., Papenburg, J., Schwartz, K. L., Scheuerman, O., . . . Staphylococcus aureus Network Adaptive Platform Paediatric and Youth (SNAP-PY) working group SNAP Global Trial Steering Committee (2024). **Whole-of-Life Inclusion in Bayesian Adaptive Platform Clinical Trials.** *JAMA pediatrics*, 178(10), 1066–1071. https://doi.org/10.1001/jamapediatrics.2024.2697

Chai, K. L., Wellard, C., Thao, L., Aoki, N., Moore, E. M., Augustson, B. M., Bapat, A., **Blacklock, H.**, Chng, W. J., Cooke, R., Forsyth, C. J., Goh, Y. T., Hamad, N., Harrison, S. J., Ho, P. J., Hocking, J., Kerridge, I., Kim, J. S., Kim, K., King, T., . . . McQuilten, Z. K. (2024). **Variation in immunoglobulin use and impact on survival in myeloma.** *EJHaem*, 5(4), 690–697. https://doi.org/10.1002/jha2.938

Fox-Lewis, A., **She, K. W.**, **She, E. W.**, **Sathiyaseelan, A.**, Vesty, A., Roberts, S. A., **Morpeth, S. C.**, **Taylor, S.**, Anderson, A., Bennett, J., Moreland, N. J., & **Webb, R.** (2025). **Capturing the complete clinical spectrum and incidence of severe acute Group A Streptococcus (GAS) disease: a population-based study in Auckland, New Zealand.** *The Lancet regional health. Western Pacific*, 59, 101600. https://doi.org/10.1016/j.lanwpc.2025.101600

Kamp, C. B., Dankiewicz, J., Harboe Olsen, M., Holgersson, J., Saxena, M., Young, P., . . . Jakobsen, J. C. (2025). **Sedation, temperature and pressure after cardiac arrest and resuscitation–The STEPCARE trial: A statistical analysis plan.** *Acta Anaesthesiol Scand*, 69(5), e70033. doi:10.1111/aas.70033

Long, E., Borland, M. L., George, S., Jani, S., **Tan, E.**, Phillips, N., . . . Paediatric Research in Emergency Departments International Collaborative, N. (2025). **External Validation of the Phoenix Sepsis Score in Children With Suspected Community-Acquired Sepsis.** *JAMA Netw Open*, 8(3), e251412. doi:10.1001/jamanetworkopen.2025.1412

McCallum, G. B., **Byrnes, C. A.**, Morris, P. S., Grimwood, K., Marsh, R. L., Chatfield, M. D., Bowden, E. R., Schutz, K. L., Sarmiento, N., Fancourt, N., Francis, J., Zhao, Y., Vieira, A., Hare, K. M., Bonney, D., **Trenholme, A.**, **Lawrence, S.**, Marwick, F., Karvonen, B., MacLennan, C., . . . Chang, A. B.

(2025). **Azithromycin to prevent acute lower respiratory infections among Australian and New Zealand First Nations and Timorese children (PETAL trial): study protocol for a multicentre, international, double-blind, randomised controlled trial.** *BMJ open*, 15(2), e097455. https://doi.org/10.1136/bmjopen-2024-097455

Pearson, A. G., Pearson, J. F., Lewis, L. K., Fa'atoese, A., Poppe, K. K., Pemberton, C., Devlin, G., **Lund, M.**, Richards, A. M., Troughton, R., & Doughty, R. N. (2025). **Lower NT-proBNP plasma concentrations in Pacific peoples with heart failure.** *ESC heart failure*, 12(4), 2976–2984. https://doi.org/10.1002/ehf2.15314

Phillips, N., Askin, G. N., Davis, G. A., O'Brien, S., Borland, M. L., Williams, A., Kochar, A., John-Denny, B., Watson, S., George, S., Davison, M., Dalziel, S., **Tan, E.**, Chong, S. L., Craig, S., Rao, A., Donath, S. M., Selman, C. J., Goergen, S., Wilson, C. L., . . . Babl, F. E. (2025). **Prospective observational study to assess the performance accuracy of clinical decision rules in children presenting to emergency departments with possible cervical spine injuries: the Study of Neck Injuries in Children (SONIC).** *BMJ open*, 15(5), e096294. https://doi.org/10.1136/bmjopen-2024-096294

Saito, S., Bennett, J., Nef, H. M., Webster, M., Namiki, A., Takahashi, A., Kakuta, T., Yamazaki, S., Shibata, Y., **Scott, D.**, Vrolix, M., Menon, M., Möllmann, H., Werner, N., Neylon, A., Mehmedbegovic, Z., Smits, P. C., Morice, M. C., Verheye, S., & BIOADAPTOR-RCT Collaborators (2025). **Percutaneous Coronary Treatment With Bioadaptor Implant vs Drug-Eluting Stent: 2-Year Outcomes From BIOADAPTOR RCT.** *JACC. Cardiovascular interventions*, 18(8), 988–997. https://doi.org/10.1016/j.jcin.2025.01.426

Selvarajah, V., Robertson, D., Hansen, L., Jermutus, L., Smith, K., Coggi, A., Sánchez, J., Chang, Y. T., Yu, H., Parkinson, J., Khan, A., Chung, H. S., Hess, S., Dumas, R., Duck, T., Jolly, S., Elliott, T. G., **Baker, J.**, Lecube, A., Derwahl, K. M., . . . study investigators (2024). **A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.** *Kidney international*, 106(6), 1170–1180. https://doi.org/10.1016/j.kint.2024.08.023

Toomata, Z. L. L., Jiang, Y., Yeu, R. Q., Brandon, R., Tweedie-Cullen, R. Y., Nehren, N., . . . **Murphy, R.** (2025). **Reduced Weight Gain with Pioglitazone vs Vildagliptin in CREBRF rs373863828 A-allele Carriers: Insights from the WORTH Trial.** *Diabetes Metab Syndr Obes*, 18, 1255–1262. doi:10.2147/DMSO.S500336

Webb, E. M., Holland, A. E., Chang, A. B., Middleton, P. G., Thomson, R., **Wong, C.**, . . . Lee, A. L. (2025). **Pediatric physiotherapy management of airway clearance therapy and exercise: Data from the Australian Bronchiectasis Registry.** *Pediatr Pulmonol*, 60(1), e27370. doi:10.1002/ppul.27370

Yuen, M. F., Lim, Y. S., Yoon, K. T., **Lim, T. H.**, Heo, J., Tangkijvanich, P., . . . Gane, E. (2024). **VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study.** *Lancet Gastroenterol Hepatol*. doi:10.1016/S2468-1253(24)00237-1

Sponsors and CROs

SPONSORS:



CROs:



PARTNERS:





MIDDLEMORE HOSPITAL

Phone: 0800 ENROLL (0800 367 655)

Email: info@aotearoatrials.nz

Physical address:

Esme Green, Middlemore Hospital,
100 Hospital Road, Otahuhu,
Auckland 2025

WHANGĀREI HOSPITAL

Phone: 09 4304101

Email: info@aotearoatrials.nz

Physical Address:

Maunu House, Maunu Road,
Horahora, Whangārei 0148

www.aotearoatrials.nz

